Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
HOUSTON, May 4, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its...
Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject Positive results from first cohort allows Company to progress to second cohort in Phase 1b portion of the Phase 1b/2 trial with 230 mg/m2 dose of Annamycin HOUSTON,...
Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models
Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 Annamycin demonstrated increased penetration and accumulation in the liver, which correlated with high antitumor activity in HEPA 1-6...
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
- 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs - Sufficient capital to fund operations into the third quarter of 2024 - Company to host conference call and webcast today at 8:30 AM ET...
Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
- Actively recruiting in three Phase 1b/2 clinical trials (with one now in Phase 2) and have recently concluded one trial - Reached 50% recruitment of Phase 2 portion of soft tissue sarcoma (STS) lung metastases trial - Multiple expected milestones and interim data...
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
HOUSTON, March 21, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that an...
Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast
HOUSTON, March 15, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will...
Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference
Presentation with live video webcast on Tuesday, March 14th at 12:40 PM ET HOUSTON, March 13, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical...
Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation
HOUSTON, March 13, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it is aware...
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Annamycin appears to be a highly promising non-cardiotoxic, potent TOPO-II inhibitor able to overcome MDR-1 that, due to its unique organotropism, is also able to target hard-to-treat metastasis In an independent expert cardiology review of 42 subjects evaluated as of...